On December 3, 2024 Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, reported that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC) (Press release, Epsilogen, DEC 3, 2024, View Source [SID1234648748]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase Ib, open-label, dose escalation and expansion trial (NCT06547840) will enrol 45 patients with PROC whose disease has progressed after no more than four lines of prior therapy. The trial will assess the safety, tolerability and efficacy of MOv18 IgE in ascending dose cohorts.

MOv18 IgE is an IgE antibody targeting the folate receptor alpha (FR alpha) antigen which is selectively expressed by a variety of cancers including ovarian, non-small cell lung, endometrial and triple negative breast cancer. It is the first ever IgE antibody therapeutic to enter clinical testing and the Phase Ib trial will generate extensive translational data to allow further understanding of IgE’s unique mechanism of action in man. A previous Phase I safety study of MOv18 IgE found it to be safe and well tolerated, with evidence of anti-tumour activity observed, as reported in Nature Communications (View Source).

Dr Tim Wilson, CEO of Epsilogen, said: "We are pleased to have initiated the Phase Ib study of MOv18 IgE, following the encouraging Phase I data. This is a key step in our goal of bringing this exciting new therapeutic modality to cancer patients".